Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMPXOYJ)

Drug Name

CPI-0610 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Myelofibrosis	2A20.2	Phase 3	[1]
Acute myeloid leukaemia	2A60	Phase 1/2	[2]
Myelodysplastic neoplasm	2A60	Phase 1/2	[2]
Myeloproliferative neoplasm	2A20	Phase 1/2	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bromodomain and extraterminal domain protein (BET)	TTE4BSY	NOUNIPROTAC	Inhibitor	[2]
Bromodomain-containing protein 4 (BRD4)	TTRA6BO	BRD4_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Bromodomain-containing protein 4 (BRD4)	DTT	BRD4	6.686	6.622	6.963	6.725

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Myelofibrosis

ICD Disease Classification

2A20.2

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Bromodomain-containing protein 4 (BRD4)	DTT	BRD4	3.27E-01	0.02	0.04

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04603495) Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.